Dr. Raymond Douglas reveals groundbreaking research on spacing teprotumumab doses to safeguard hearing in patients with thyroid eye disease, potentially transforming treatment protocols.

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN FRANCISCO and SUZHOU, China, Oct. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced today that its independently developed recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, SYCUME® (Teprotumumab N01 Injection, R&D code: IBI311), has achieved its primary study endpoint at Week 24 in a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study (RESTORE-3) in Chinese participants with inactive thyroid eye disease (TED). In this study, SYCUME® demonstrated remarkable efficacy in reducing proptosis in participants with inactive TED, with a favorable safety profile. SYCUME® is the first IGF-1R antibody drug in China and the second one approved worldwide, filling a 70-year treatment gap in the domestic TED field. Officially included in China's National Reimbursement Drug List on January 1, 2026, SYCUME® substantially alleviates the financial burden on patients compared to the high cost of overseas counterparts, significantly enhancing drug accessibility. Patients with inactive TED account for...

Teprotumumab is the first FDA-approved biologic for moderate-to-severe thyroid eye disease (TED). Although efficacy has been established in randomized controlled trials (RCTs), real-world studies (RWS) have reported different efficacy and safety patterns, supporting an updated synthesis.

Teprotumumab, the first approved therapy for thyroid eye disease, is highly effective, but has been increasingly associated with otologic adverse events, prompting a United States Food and Drug Administration warning regarding hearing impairment in 2023. Reported incidence varies widely across studies, and the true burden of toxicity remains uncertain. We conducted a systematic review and meta-analysis of PubMed/MEDLINE, Embase, and Cochrane CENTRAL from inception through May, 2026 (PROSPERO CRD420261337579), identifying 22 eligible studies (5 randomized controlled trials and 17 observational studies) comprising 856 teprotumumab-treated patients.

试剂级 Teprotumumab 市场概览： 2023 年试剂级 Teprotumumab 市场规模估计为 0.08（十亿美元）。试剂级 Teprotumumab 市场行业预计将从 2024 年的 0.11（十亿美元）增长到 2032 年的 1.5（十亿美元）。预测期内试剂级 Teprotumumab 市场 CAGR（增长率）预计约为 39.39% | Wiseguy Reports

The Reagent Grade Teprotumumab Market is expected to grow from 500 USD Million in 2025 to 1,500 USD Million by 2035. The Reagent Grade Teprotumumab Market CAGR (growth rate) is expected to be around 1...

Read the full paper: Teprotumumab effects on thyroid eye disease in a Japanese MRI study: comparison with intravenous glucocorticoid therapy

Eye, Published online: 05 August 2026; doi:10.1038/s41433-026-04803-8Infographic: a randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients

.

Thyroid eye disease (TED) is an autoimmune orbital disease characterized by autoantibody-mediated activation of orbital fibroblasts and CD34+ fibrocytes, triggering orbital inflammation and tissue remodeling through proposed crosstalk between the thyroid-stimulating hormone receptor and insulin-like growth factor-1 receptor (IGF-1R) signaling complex.1 This mechanistic framework shifted the paradigm of active TED management in the past decade through the introduction of teprotumumab,2 which is a partial antagonist monoclonal antibody to IGF-1R.

To describe patient characteristics and teprotumumab treatment patterns among patients with thyroid eye disease.

Official answer: In studies of people taking Tepezza (teprotumumab-trbw) for thyroid eye disease (TED), some but not all patients began...

Eye, Published online: 03 July 2026; doi:10.1038/s41433-026-04696-7Infographic: efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity

Teprotumumab for thyroid eye disease (TED) appears to worsen glycemic control even in individuals with normal blood glucose levels.

A recent study found that in patients with thyroid eye disease (TED) who relapse, receiving teprotumumab during the active phase, vs during the stable phase, appeared to lead to a more severe and prolonged disease relapse course.